Drug intelligence / Profile preview

JRD-028

Development stage: Preclinical
Lead developer: Jingrui Pharmaceutical
Modality: Small Molecules

Overview

JRD-028 is a small molecule drug candidate developed by Jingrui Pharmaceutical (Suzhou Co. Ltd.) that acts as a modulator of the KRAS G12D mutant protein, a well-known oncogenic driver in several cancers. The drug is being investigated for its potential to inhibit the activity of KRAS G12D, thereby targeting tumor growth and progression in cancers where this mutation is prevalent, such as lung cancer and pancreatic cancer. As of early 2025, its highest development status is preclinical[1][2].

Other names: JRD-028JRD028JRD 028

Targets

KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)

Beyond the preview

Go deeper on JRD-028.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JRD-028.

Explore the full profile